Magazine article Clinical Psychiatry News

Can't Get Enough Policy & Practice? Check out Our New Podcast Each Monday

Magazine article Clinical Psychiatry News

Can't Get Enough Policy & Practice? Check out Our New Podcast Each Monday

Article excerpt

CMS Adds Geriatric Code

The Centers for Medicare and Medicaid Services has established a new physician specialty code for geriatric psychiatry. The code, 27, will go into effect April 1, 2010, the agency announced in late October. CMS directed all its contractors to recognize the new physician specialty code on all claims.

Dr. Nemeroff Lands in Miami

Dr. Charles B. Nemeroff, who was hounded by charges of conflicts of interest in his biological studies of neuropsychiatric disorders, has left Emory University, Atlanta, for the University of Miami. He will be professor and chairman of the department of psychiatry and behavioral sciences. While at Emory, Dr. Nemeroff was accused of failing to disclose $800,000 in payments from GlaxoSmithKline while he was directing National Institutes of Health studies that used some of that company's products. Emory subsequently stripped him of his psychiatry chairmanship and blocked him from seeking NIH grants for 2 years. It also prompted Emory to revise its conflict rules. According to a statement from Miami's Miller School of Medicine, Dr. Nemeroff plans to work on mental health and aging, HIV drug abuse, and links between depression and cancer and heart disease.

Shire Receives OIG Subpoena

The British-based pharmaceutical company Shire plc has received a subpoena from the Office of the Inspector General of the U.S. Department of Health and Human Services seeking documents related to the sales and marketing of Adderall XR (amphetamine/dextroamphetamine), Day-trana (methylphenidate), and Vyvanse (lisdexamfetamine). Shire disclosed the subpoena in a statement with its third-quarter 2009 earnings announcement, which said sales of Adderall XR dropped 74% in the quarter. But Vyvanse sales continued to grow, partly because of the Food and Drug Administration's rejection of a generic competitor earlier this year and partly because of a 10% growth in the market for attention-deficit/hyperactivity disorder treatments, Shire said. The company also said it is about to launch its latest drug for ADHD, Intuniv (guanfacine).

Huge Seroquel Settlement

AstraZeneca will pay $520 million to settle several legal proceedings relating to its atypical antipsychotic Seroquel (quetiapine). The settlement was for two federal investigations and two whistleblower (qui tam) suits. In its third quarter-2009 earnings filing, the company said that the qui tam suits were related to two investigations by the U.S. Attorney's Office in Philadelphia. One concerns off-label sales and marketing, and the second is about "selected physicians who participated in clinical trials involving Seroquel," the company said. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed


An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.